Progen gets in synth
By Dylan Bushell-Embling
Wednesday, 02 July, 2008
Wednesday, 02 July, 2008
Brisbane biotech Progen Pharmaceuticals (ASX: PGL) has spun out its manufacturing business into a wholly-owned subsidiary.
The new subsidiary will be called PharmaSynth, and will be responsible for completing Progen's PI-88 manufacturing process.
It will also offer process development and manufacturing services to the biotechnology industry.
Progen's former director of manufacturing operations, Les Tillack, is the new company's CEO.
Related News
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
